Robert Zeiser, MD, professor, head, Department of Tumor Immunology and Immune Regulation, Clinic for Internal Medicine I, University Medical Center Freiburg, discusses results of the REACH3 trial in chronic graft-versus-host disease (cGVHD).

Results of the randomized, phase 3 REACH3 trial, which were presented ​virtually during the 2020 ASH Annual Meeting ​& Exposition, demonstrated a significantly higher overall response rate with ruxolitinib (Jakafi) vs best available therapy (BAT), at 49.7% and 25.6%​, respectively. Moreover, 6.7%​ of patients achieved a complete response (CR)​ with ruxolitinib compared with 3% of patients with BAT, Zeiser says.

 Furthermore, the safety profiles were similar between arms. The most common ​any-grade adverse effects​ observed with ruxolitinib or BAT, respectively, ​included anemia (​29.1% vs 12.7%), thrombocytopenia (21.2% vs 14.6%), hypertension (​15.8% vs 12.7%), pyrexia (15.8% vs 9.5%), and alanine aminotransferase increase (15​.2% vs 4​.4%). Infections occurred in 64% of patients with ruxolitinib vs 56% of patients with BAT, Zeiser concludes.

Videos

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

Robert Zeiser, MD,

Articles

Dr. Zeiser on Results of the REACH3 Trial in Chronic GVHD